Corbus Pharmaceuticals Holdings IncCorbus Pharmaceuticals Holdings Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

Browse to the bottom of this webpage for potential risks for Corbus Pharmaceuticals Holdings Inc based on industry, location and size. The webpage displays a zero-cost E,S&G assessment for Corbus Pharmaceuticals Holdings Inc. This ESG score covers 17 United Nations Sustainable Development Goals including: 'Zero Hunger', 'Sustainable Cities & Communities' and 'Life below Water'.

Corbus Pharmaceuticals Holdings Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.2; made up of an environmental score of 4.0, social score of 4.0 and governance score of 4.6.

SDG Transparency Score for Corbus Pharmaceuticals Holdings Inc 
Low
0 - 3

4.2

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Corbus Pharmaceuticals Holdings Inc 
4.0

Environmental

4.0

Social

4.6

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
1335PureTech Health PLC
4.3
High
1335Youcare Pharmaceutical Group Co Ltd
4.3
High
1376Corbus Pharmaceuticals Holdings Inc
4.2
High
1376Atreca Inc
4.2
High
1376BiondVax Pharmaceuticals Ltd
4.2
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Corbus Pharmaceuticals Holdings Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc offer flexible work?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose water use targets?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Corbus Pharmaceuticals Holdings Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Corbus Pharmaceuticals Holdings Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Corbus Pharmaceuticals Holdings Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose its waste policy?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose energy use targets?

LockedSign up for free to unlock

Does Corbus Pharmaceuticals Holdings Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Corbus Pharmaceuticals Holdings Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Corbus Pharmaceuticals Holdings Inc
These potential risks are based on the size, segment and geographies of the company.

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Sorry!

Failed to process!